期刊
TISSUE ENGINEERING PART C-METHODS
卷 16, 期 3, 页码 459-467出版社
MARY ANN LIEBERT, INC
DOI: 10.1089/ten.tec.2009.0112
关键词
-
资金
- NIH [R01 HL083880]
- NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL083880] Funding Source: NIH RePORTER
Current methods for measuring collagen content in engineered tissues are incompatible with monitoring of collagen production because they require destruction of the tissue. We have implemented a luciferase-based strategy to monitor collagen production noninvasively. Fibrin-based tissue constructs made using vascular smooth muscle cells stably transfected with a collagen I promoter/luciferase transgene developed with collagen content comparable to control cells, but could be imaged noninvasively to follow collagen transcription during tissue growth in vitro. We showed that these cells reported collagen I production at the transcriptional level in response to the growth factor transforming growth factor-beta 1 and fibrinolytic inhibition by e-aminocaproic acid and that these changes were consistent with changes at the mRNA and protein levels. As these cells report collagen changes instantly and without tissue destruction, they will facilitate construct optimization using multiple stimuli to produce functional engineered tissues.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据